Review article: Role of proton pump inhibitors in non-H. pylori-related ulcers

Alimentary Pharmacology and Therapeutics

Volumn 15, Issue SUPPL. 2, 2001, Pages 2-5

  Freston, J W ^a  

^a UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIULCER AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; PROTON PUMP;

DRUG ANTAGONISM; DUODENUM ULCER; HUMAN; PREVALENCE; REVIEW; UNITED STATES;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTI-ULCER AGENTS; DUODENAL ULCER; HUMANS; PREVALENCE; PROTON PUMPS; UNITED STATES;

EID: 1042293806     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2036.2001.00114.x     Document Type: Review

References (22)

1. Laine L, Hopkins RJ, Girardi LS. Has the impact of Helicobacter pylori therapy on ulcer recurrence in the united States been overstated? A meta-analysis of rigorously designed trials. Am J Gastroenterol 1998; 93: 1409-15.
2. Harford W, Lanza F, Arora A, et al. Double-blind, multi-center evaluation of lansoprazole and amoxicillin dual therapy for the cure of Helicobacter pylori infection. Helicobacter 1996; 1(4): 243-50.
3. Peterson WL, Ciociola AA, Sykes DL, et al., H. pylori Study Group. Ranitidine mismuth citrate plus clarithromycin is effective for healing duodenal ulcers, eradicating H. pylori and reducing ulcer recurrence. Aliment Pharmacol Ther 1996; 10: 251-62.
4. Sprung DJ, Gabo B. The natural history of duodenal ulcer disease and how it related to H. pylori - a community study. Am J Gastroenterol 1997; 92: A286 (Abstract).
5. Jensen DM, King J, Gornbein J, Cheng S. Prevalence of H. pylori and aspirin or NSAID utilization in patients with ulcer hemorrhage: results of screening for a large multicenter US trial. Gastroenterol 1997; 114: A161 (Abstract).
6. Jyotheeswaran S, Shah AN, Jin HO, Potter GD, Ona FV, Chey WY. Prevalence of Helicobacter pylori in peptic ulcer patients in greater Rochester, NY: is empirical triple therapy justified? Am J Gastroenterol 1998; 93: 574-8.
7. Schubert ML. H. pylori and nonulcer dyspepsia: not guilty as charged. Gastroenterology 1999; 117(1): 270-2.
8. Ciociola AA. Helicobacter pylori infection rates in duodenal ulcer patients in the united States may be lower than previously estimated. Am J Gastroenterol 1999; 94: 1834-40.
9. McColl KEL, El-Nujumi AM, Chittajallu RS, et al. A study of the pathogenesis of Helicobacter pylori negative chronic duodenal ulceration. Gut 1993; 34: 762-8.
10. Henry A, Batey RG. Low prevalence of Helicobacter pylori in an Australian duodenal ulcer population: NSAIDitis or the effect of ten years of H. pylori treatment? Aust NZ J Med 1998, June; 28(3): 345.
11. Gisbert JP, Blanco M, Mateos JM, et al. H. pylori-negative duodenal ulcer prevalence and causes in 774 patients. Dig Dis Sci 1999; 44(11): 2295-302.
12. Xia HH, Talley NJ. Helicobacter pylori eradication in patients with non-ulcer dyspepsia. Drugs 1999; 58(5): 785-92.
13. Tsuji H, Kohli Y, Fukumitsu S, et al. Helicobacter pylori-negative gastric and duodenal ulcers. J Gastroenterol 1999; 34(4): 455-60.
14. Meucci G, Di Battista R, Abbiati C, et al. Prevalance and risk factors of Helicobacter pylori-negative peptic ulcer: a multicenter study. J Clin Gastroenterol 2000; 31(1): 42-7.
15. Bytzer P, Teglbjaerg PS, Danish Ulcer Study Group. Helicobacter pylori-negative duodenal ulcers: prevalence, clinical characteristics, and prognosis - results from a randomized trial with 2-year follow-up. Am J Gastroenterol 2001; 96(5): 1409-16.
16. Sugiyama T, Nishikawa K, Komatsu Y, et al. Attributable risk of H. pylori in peptic ulcer disease: does declining prevalence of infection in general population explain increasing frequency of non-H. pylori ulcers? Dig Dis Sci 2001; 46(2): 307-10.
17. Harris AW, Gummett PA, Phull PS, Jacyna MR, Misiewicz JJ, Baron JH. Recurrence of duodenal ulcer after Helicobacter pylori eradication is related to high acid output. Aliment Pharmacol Ther 1997; 11(2): 331-4.
18. Blum RA, Shi H, Karol MD, Greski-Rose PA, Hunt RH. The comparative effects of lansoprazole, omeprazole, and ranitidine in suppressing gastric acid secretion. Clin Ther 1997; 19(5): 1013-23.
19. Graham DY, Yamaoka Y. H. pylori and CagA: relationships with gastric cancer, duodenal ulcer, and reflux esophagitis and its complications. Helicobacter 1998; 3: 145-52.
20. Labenz J, Tillenburg B, Peitz U, et al. Efficacy of omeprazole one year after cure of Helicobacter pylori infection in duodenal ulcer patients. Am J Gastroenterol 1997; 92: 576-8.
21. Olmos M, et al. Lansoprazole vs. omeprazole in speed of duodenal ulcer healing. Gut 1997; 41(Suppl. 3): A97 (Abstract).
22. Lanza F, Goff J, Silvers D, et al. Prevention of duodenal ulcer recurrence with 15 mg lansoprazole; a double-blind placebo-controlled study. The Lansoprazole Study Group. Dig Dis Sci 1997; 42(12): 2529-36.